||| Menü 
Firmenveranstaltungen, Neuemissionen

Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

Fusionen, Übernahmen

Personal, Belegschaft, Meldungen zu Produkten


Bankleitzahlen - online.de

At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth

Novartis International AG /
At the Meet Novartis Management investor event, Novartis highlights strategy to
focus the company and drive sustainable growth
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.

* Full pipeline of late stage assets with blockbuster potential

* Positioned to deliver sales growth and margin expansion through 2022

* Pipeline depth in key therapeutic areas and building new, distinctive
platform capabilities

* Alcon returning to a position of strength as the world's leading eye care
devices company

Basel, May 16, 2018 - Today Novartis holds its annual Meet Novartis Management
event at its global headquarters in Basel, Switzerland, giving investors and
analysts the opportunity to meet with key executives across the company in six
separate breakout sessions. The meeting provides a deeper view into the
company's strategy for sustainable value creation, and addresses investors'
questions via an open Q&A format.

"We would like to thank all our investors for their commitment to our company.
We are excited and confident that our portfolio of novel medicines, together
with our strategy to become a more focused medicines company, will result in
sustainable top and bottom line growth. We also have made mistakes recently and
the world rightly expects more from a leading healthcare company. Our new
executive team and I have a deep commitment to ensure we always operate with the
highest integrity and sound judgment and will work hard to rebuild lasting trust
with society," said Novartis CEO, Vas Narasimhan M.D.

For the Innovative Medicines Pharmaceuticals business unit, management
highlights Cosentyx and Entresto, as well as 10 potential blockbuster launches
in the next three years including Aimovig, BAF312 and RTH258. Cosentyx has taken
NBRx leadership in Rheumatology (PsA and AS) where IL-17A has shown strong
lasting efficacy and a favorable safety profile. Head-to-head superiority trials
of Cosentyx vs. adalimumab in PsA and AS are ongoing. Entresto sales have
continued to build with a growing body of evidence showing Entresto helps
patients live longer and have a better quality of life.

The Innovative Medicines Oncology business unit returned to growth with sales
+6% (cc) in Q1 2018, driven by Tafinlar + Mekinist, Promacta and Jakavi. Three
new potential blockbuster launches, Kisqali, Kymriah and Lutathera, are expected
to further drive growth in the mid-term. Oncology is expected to have 15 major
filings and 13 approvals in 2018 and sizable filing opportunities in 2019,
including SEG101 and PDR001 + Tafinlar + Mekinist.

In Sandoz, management highlights continued leadership in biosimilars and plans
for major launches in the US and Europe. Despite continuing US pricing pressure,
globally, the Sandoz gross margin is improving, driven by an increased focus on
higher-margin portfolio segments and geographies, as well as productivity. In
the US, Sandoz is optimizing the portfolio through targeted pruning and learning
from recent setbacks. Outside the US, growth continues across regions and Sandoz
is the market leader in Europe.

In Alcon, management highlights the actions that have returned the business to
growth and improved margins.  Alcon is the global market leader in eye care
devices, with leading global sales positions in the growing Surgical and Vision
Care markets. With continued innovation, investment and improved operations,
Alcon expects to return to long-term, sustainable growth with margins in line
with industry peers. The strategic review is on track with action not expected
before the first half of 2019.

Novartis has a strong track record of R&D excellence, including being #1 in
US/EU approvals over the last 10 years. The Global Drug Development (GDD) team
provides insight into the full pipeline of late stage assets with blockbuster
potential. These late stage assets are followed up with a strong and diverse set
of emerging phase II assets from the Novartis Institutes for Biomedical Research
(NIBR). Novartis is building new platform capabilities in advanced therapies and
leveraging internal and external innovation to build and accelerate our

In closing, Group management reiterates the overall strategy. We have taken
steps to focus the company and our capital in areas where we have the key
ingredients to lead. We announced the sale of our stake in the Consumer
Healthcare JV to GSK and invested more in gene therapy and oncology. We are
positioned to deliver sales growth and margin expansion through 2022, driven by
our key in-market products, our full late-stage pipeline and ongoing
productivity efforts. We are working to capture the potential of digital
technologies in every function. We have pipeline depth in our key therapeutic
areas, and are building new, distinctive platform capabilities for the future.
Novartis management is focused on driving our strategy and sustainable growth.

For background slides and webcast (audio only) please refer to the following
link: http://www.novartis.com/investors/event-calendar/index.shtml
The background slide decks will be available on Wednesday May 16, 2018 at 7:15
am CET.

This press release contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995, that can
generally be identified by words such as "strategy," "pipeline," "potential,"
"positioned to," "building," "commitment," "excited," "confident," "will,"
"ongoing," "expected," "plans," "optimizing," "continues," "expects," "strategic
review," "on track," "emerging," "to build and accelerate," "working to,"
"future," "sustainable," or similar expressions, or by express or implied
discussions regarding potential new products, potential new indications for
existing products, or regarding potential future revenues from any such
products; or regarding potential future sales or earnings of Novartis; or
regarding the potential outcome of the strategic review being undertaken to
maximize shareholder value of the Alcon Division; or regarding the potential
financial or other impact of the significant acquisitions and reorganizations of
recent years; or regarding potential future sales or earnings of the Novartis
Group or any of its divisions or potential shareholder returns; or by
discussions of strategy, plans, expectations or intentions. You should not place
undue reliance on these statements. Such forward looking statements are based on
our current beliefs and expectations regarding future events, and are subject to
significant known and unknown risks and uncertainties. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those set forth in the
forward looking statements. There can be no guarantee that any new products will
be approved for sale in any market, or that any new indications will be approved
for any existing products in any market, or that any approvals which are
obtained will be obtained at any particular time, or that any such products will
achieve any particular revenue levels. Neither can there be any guarantee that
the strategic review being undertaken to maximize shareholder value of the Alcon
Division will reach any particular results, or at any particular time, or that
the result of the strategic review will in fact maximize shareholder value.
Neither can there be any guarantee that Novartis will be able to realize any of
the potential strategic benefits, synergies or opportunities as a result of the
significant acquisitions and reorganizations of recent years. Neither can there
be any guarantee that shareholders will achieve any particular level of
shareholder returns. Nor can there be any guarantee that the Group, or any of
its divisions, will be commercially successful in the future, or achieve any
particular credit rating or financial results. In particular, our expectations
could be affected by, among other things: global trends toward health care cost
containment, including government, payor and general public pricing and
reimbursement pressures and requirements for increased pricing transparency;
regulatory actions or delays or government regulation generally, including
potential regulatory actions or delays with respect to the development of the
products described in this release; the potential that the strategic benefits,
synergies or opportunities expected from the proposed acquisition of AveXis,
Inc. may not be realized or may take longer to realize than expected; the
successful integration of AveXis into the Novartis Group subsequent to the
closing of the transaction and the timing of such integration; potential adverse
reactions to the proposed transaction by customers, suppliers or strategic
partners; dependence on key AveXis personnel and customers; the potential that
the strategic benefits, synergies or opportunities expected from the significant
acquisitions and reorganizations of recent years may not be realized or may take
longer to realize than expected; the inherent uncertainties involved in
predicting shareholder returns; the uncertainties inherent in the research and
development of new healthcare products, including clinical trial results and
additional analysis of existing clinical data; our ability to obtain or maintain
proprietary intellectual property protection, including the ultimate extent of
the impact on Novartis of the loss of patent protection and exclusivity on key
products which commenced in prior years and will continue this year; safety,
quality or manufacturing issues; uncertainties regarding actual or potential
legal proceedings, including, among others, actual or potential product
liability litigation, litigation and investigations regarding sales and
marketing practices, intellectual property disputes and government
investigations generally; uncertainties involved in the development or adoption
of potentially transformational technologies and business models; general
political and economic conditions, including uncertainties regarding the effects
of ongoing instability in various parts of the world; uncertainties regarding
future global exchange rates; uncertainties regarding future demand for our
products; and uncertainties regarding potential significant breaches of data
security or data privacy, or disruptions of our information technology systems;
and other risks and factors referred to in Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update any forward-looking statements as a result of new
information, future events or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2017, the Group achieved
net sales of USD 49.1 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
124,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please
visit http://www.novartis.com.


Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com

Eric Althoff Antonio Ligi
Novartis Global Media Relations Novartis Global External Communications
+41 61 324 7999 (direct) +41 61 324 1374 (office)
+41 79 593 4202 (mobile) +41 79 723 3681 (mobile)
eric.althoff@novartis.com antonio.ligi@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central   North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF):

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novartis International AG via GlobeNewswire

 ||| Themen-Infos 
· Mehr zu dem Thema Allgemeine Nachrichten

Der meistgelesene Artikel zu dem Thema Allgemeine Nachrichten:
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Sehr gut

Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.087 Sekunden